Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

631.O2.8 Chronic Myeloid Leukemia - Stem Cell Biology and Eradication

Monday, December 8, 2008: 7:00 AM-9:00 AM
2001-2003-2014-2016 - West (Moscone Center)
Moderators:
Ravi Bhatia and Danilo Perrotti, MD, PhD
7:00 AM
Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38- Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL–independent Signals

Paolo Neviani, PhD1, Ramasamy Santhanam, Ph.D1*, Yihui Ma, B.S.2*, Guido Marcucci, MD3, John C. Byrd, MD4, Ching-Shih Chen, Ph.D5*, Jorge Cortes, MD6, Michael A. Caligiuri, MD4, Claudia Huettner, PhD7*, Ravi Bhatia, MD8, Denis-Claude Roy, MD9 and Danilo Perrotti, MD, PhD1

1Comprehensive Cancer Center, The Ohio State University, Columbus, OH
2Pharmacy, The Ohio State University, Columbus, OH
3Dept. of Hematology/ Oncology, The Ohio State Univ. Med. Ctr., Columbus, OH
4The Ohio State University, Columbus, OH
5College of Pharmacy, Ohio State University, Columbus, OH
6M.D. Anderson Cancer Center, Houston, TX
7Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI
8Hem/HCT, City of Hope National Medical Center, Duarte, CA
9Hematology-Oncology, Hopital Maisonneuve-Rosemont, Montreal, QC, Canada

7:15 AM
Suppression of CML Progenitor but Not CML Stem Cell Growth Requires Dual Inhibition of BCR-ABL and KIT

Amie S. Corbin1*, Thomas O'Hare1*, Brian J. Druker1 and Michael W.N. Deininger2

1Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute, Portland, OR
2Hematology and Medical Oncology, Oregon Health & Science University Cancer Institute, Portland, OR

7:30 AM
Leukemic Stem Cells and Progenitors Demonstrate Impaired Interaction with the Hematopoietic Microenvironment in Vivo in An Inducible Murine Model of Chronic Myelogenous Leukemia

Amitava Sengupta, PhD1* and Jose Cancelas, MD, PhD2

1Experimental Hematology, CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, Cincinnati, OH
2Hoxworth Blood Center, Univ. of Cincinnati, Cincinnati, OH

7:45 AM
Mechanisms Generating free Radicals in CML Stem/Progenitor Cell Populations Causing DNA Damage and Genomic Instability

Margaret Nieborowska-Skorska, MD, PhD1*, Mateusz Koptyra, PhD1*, Grazyna Hoser, PhD2*, Regina Ray1*, Danielle Ngaba1*, Elisabeth Bolton1* and Tomasz Skorski, MD, PhD1

1Microbiology and Immunology, Temple University, School of Medicine, Philadelphia, PA
2Clinical Cytology, Medical Center for Postgraduate Education, Warsaw, Poland

8:00 AM
Differentially Expressed and Novel Transcripts in Highly Purified Chronic Phase CML Stem Cells

Yun Zhao1*, Allen Delaney2*, Afshin Raouf1*, Kamini Raghuram1*, Haiyan I Li2*, Angelique Schnerch2*, Xiaoyan Jiang, MD, PhD1, Allen C Eaves1*, Marco A Marra, PhD2 and Connie J. Eaves, PhD1

1Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
2Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada

8:15 AM
Persistence of Leukemia Stem Cells in Chronic Myelogenous Leukemia Patients in Complete Cytogenetic Remission on Imatinib Treatment for 5 Years

Su Chu, MD*, Allen Lin*, Tinisha McDonald*, David S. Snyder, MD, Stephen J. Forman, MD and Ravi Bhatia, MD

Division of Hematology and HCT, City of Hope National Medical Center, Duarte, CA

8:30 AM
Selective Anti-Leukemia Targeting of the Interaction Between BCR/ABL and Mammalian RecA Homologs

Artur Slupianek, PhD, Shuyue Ren, MD, PhD and Tomasz Skorski, MD, PhD

Microbiology and Immunology, Temple University, Philadelphia, PA

8:45 AM
Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients

Jane R Engler*, Amity Frede*, Andrew C W Zannettino, PhD*, Deborah L White, PhD* and Timothy P Hughes, MD

Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia

*signifies non-member of ASH